Abstract
The burden of malignant pleural disease continues to rise, and the discovery of a malignant pleural effusion is a common problem in patients with lung cancer and malignant pleural mesothelioma. Symptomatic pleural involvement can present clinicians with a number of diagnostic and therapeutic challenges. Radiologically apparent pleural involvement requires thorough investigation and its discovery commonly represents metastatic disease across many tumour types. Histopathological pleural molecular subtyping has dramatically increased the availability of novel targeted therapies in advanced thoracic malignancy, and modern pleural intervention strategies can offer patients timely evidence-based fluid management. The impact of modern pleural research has reshaped the way in which patients are managed, shifting from what was historically a more surgical and radiological domain to the more medically focused approach. Developing pleural teams are in an excellent position to influence change in the current economically challenging environment by providing this group of patients with advanced disease, rapid management in an ambulatory setting. The use of validated prognostication tools and image-guided symptom control strategies help us to offer our patients more individualised pleural management. The chapter aims to summarise the available data around the pathophysiological mechanisms of pleural fluid production whilst considering methods of investigation, tumour staging and prognostication through to patient focused, therapeutic intervention strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bhatnagar R, Maskell N. Developing a ‘pleural team’ to run a reactive pleural service. Clin Med. 2013;13(5):452–6.
Bhatnagar R, Maskell N. The modern diagnosis and management of pleural effusions. Br Med J. 2015;351:h4520:1–8.
Bhatnagar R, Cocoran JP, Maldonado F, Feller-Kopam D, Janssen J, Astoul P, Rahman NM. Advanced medical interventions in pleural disease. Eur Respir Rev. 2016;25(140):199–213.
Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–104.
Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016;5:CD010529.
Davies HE, Mishra EK, Brennen CK, Wrightson JM, Stanton AE, Guhan A, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnoea in patients with malignant pleural effusion: Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnoea in patients with malignant pleural effusion. The TIME2 randomised control trial. J Am Med Assoc. 2012;307(22):2383–9.
Delgermaa V, Takahashi K, Park E, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):701–76.
Glisson BS, Byers LA. Pathobiology and staging of small cell carcinoma of the lung. 2017. https://www.uptodate.com/contents/pathobiology-and-staging-of-small-cell-carcinoma-of-the-lung. Accessed 12 Feb 2018.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhard WEE, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol. 2015;11(1):39–51.
Hooper C, Lee YGC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society guideline. Thorax. 2010;65:ii4–17.
Lamont T, Ml S-P, Scarpello J, Durand M, Hooper C, Maskell N, et al. Insertion of chest drains: summary of a safety report from the National Patient Safety Agency. Br Med J. 2009;339:b4923.
Light RW, Macgregor MI, Luchsinger PC, Wilmot C, Ball JR. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(44):507–13.
Lim RBL. End of life care in patients with advanced lung cancer. Ther Adv Respir Dis. 2016;10(5):455–67.
Maldonado F, Lentz RJ, Light RW. Diagnostic approach to pleural diseases: new tricks for an old trade. F1000Res. 2017;1135:1–6.
Maskell N. Treatment options for malignant pleural effusion: patient preference does matter. J Am Med Assoc. 2012;307(22):2432–3.
Mishra A, Davies HE, Lee YCG. Malignant pleural disease in primary lung cancer. Eur Respir Mon. 2009;44:318–35.
Mordant P, Arame A, Legras A, Le Pimpec A, Barthes F, Riquet M. Pleural lymphatics and effusions. Rev Pneumol Clin. 2013;69(3):175–80.
Mountain CF, Hermes KE. The role of imaging in lung cancer. Cancer Imaging. 2008;1:163–70.
National Institute for Clinical Excellence. Quality standard for lung cancer in adults. 2012. www.nice.org.uk/guidance/qs17. Accessed 4 Feb 2018.
National Institute for Clinical Excellence. Suspected cancer; recognition and referral. 2015. https://www.nice.org.uk/guidance/ng12/resources/suspected-cancer-recognition-and-referral-pdf-1837268071621. Accessed 12 Feb 2018.
National Institute for Clinical Excellence CG 121. Lung cancer: diagnosis and management. 2011. https://www.nice.org.uk/guidance/cg121/resources/lung-cancer-diagnosis-and-management-pdf-35109444863941. Accessed 12 Feb 2018.
National Lung Cancer Audit annual report 2017. Royal College of Physicians. Healthcare Quality Improvement Partnership (HQIP). 2018. Accessed 4 Feb 2018.
Negrini D. Physiology and pathophysiology of the pleural space. In: Astoul P, Tassi G, Tschopp JM, editors. Thoracoscopy for pulmonologists. Berlin, Heidelberg: Springer; 2014.
Ost DE, Niu J, Zhao H, Grosu HB, Giordano SH. Quality gaps and comparative effectiveness of management for recurrent malignant pleural effusions. Chest. 2018;153(2):438–52.
Porcel JM, Esquerda A, Vives M, Bielsa S. Aetiology of pleural effusions: analysis of more than 3000 consecutives thoracentesis. Archivos de BronconeumologÃa. 2014;50(5):161–5.
Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos T. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25:189–98.
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ on behalf of the BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline. Thorax. 2010;65(Suppl 2):ii32–40.
Rushton L. The global burden of occupational disease. Curr Environ Health Rep. 2017;4:340–8.
Schiech L. Malignant pleural effusions. 2015. http://www.theoncologynurse.com/ton-issue-archive/2015-issues/march-vol-8-no-2/16361-malignant-pleural-effusions. Accessed 12 Feb 2018.
Thomas KW, Gould MK. Overview of the initial evaluation, diagnosis and staging of patients with lung cancer. 2018. https://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer. Accessed 12 Feb 2018.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65(2):87.
Travis WD, Brambilla MD, Nicolson AG, Yasushi Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organisation classification of lung tumours. Impact of genetic, clinical and radiographic advances since the 2004 classification. J Thorac Radiol. 2015;10(9):1243–60.
Walker S, Bibby A, Maskell N. Current best practice in the evaluation and management of malignant pleural effusions. Therapeutic Advances in Respiratory Disease. 2017:105–14. https://doi.org/10.1177/1753465816671697.
Wilczynska MM, Davies HE. Management of a refractory malignant pleural effusion in a patient with small cell lung cancer: a case report. Int J Respir Pulm Med. 2015;2:2–3.
Woolhouse I, Bishop L, Darlison L, De Foneska D, Edey A, Edwards J, et al. British Thoracic Society guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73(i):1–130.
World Health Organisation. Key cancer facts. 2018. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 12 Feb 2018.
Yim APC, Ng CSH. Lung cancer staging. In: Schwab M, editor. Encyclopedia of cancer. Berlin, Heidelberg: Springer; 2011.
Zamboni MM, Teixeria da Silva C, Baretta R, Cunha ET, Cardosa GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med. 2015;15:29.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Parsonage, M. (2019). Management of Pleural Burden in Metastatic Lung Cancer and Malignant Pleural Mesothelioma. In: Charnay-Sonnek, F., Murphy, A. (eds) Principle of Nursing in Oncology . Principles of Specialty Nursing. Springer, Cham. https://doi.org/10.1007/978-3-319-76457-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-76457-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-76456-6
Online ISBN: 978-3-319-76457-3
eBook Packages: MedicineMedicine (R0)